Outlook
In order to move AnTigone concept forward we need evidence at several levels:
- Enzymes performing the intended conversion
- The conversion reduces androgen receptor activity
- Enough accessible substrate is present in the intestine for the intervention to have a meaningful effect.
Our next steps therefore focus on connecting molecular activity to physiological relevance, while addressing selectivity, containment and safety.
Questions we leave behind
How much testosterone circulates through the gut?
This question came up repeatedly in our interviews, and none of the experts we have spoken with could provide a clear answer. Angelica Lindén Hirschberg confirmed that the gut is a major route of androgen elimination and that androgens undergo enterohepatic circulation, but could not say how much. Anna Benrick raised the same uncertainty.
This topic still remains unresolved in endocrinology, and it directly limits our project. Without that number, we cannot claim whether our gut-localized therapeutic could achieve a biologically meaningful effect, since we have no clear indication of how much testosterone is available in the gut for a 5β-reduction.
Can a 5β-reductase be engineered to be steroid-selective?
One of the major limitations we have encountered in our project is that 5β-reductases are not steroid specific, and engineering them to improve selectivity would require great effort. During our interview with Trevor M. Penning, he explained the reason behind it: any substrate with a Δ4-3-ketosteroid structure is a plausible 5β-reduction substrate, and achieving single-steroid specificity would require multiple point mutations across the binding pocket rather than a single one. He also cautioned that this would be an extremely difficult task within the timeline of the project.
We performed rational mutagenesis and molecular docking to identify potential ci2350 mutations to improve its selectivity for testosterone. Unfortunately, we were not able to test them experimentally. Whether selectivity on Δ4-3-ketosteroid reductases can be achieved remains an open question, and the mutations we have designed could serve as a starting point.
Is an engineered probiotic safe for consumption by pregnant women?
Following advice from Angelica Lindén Hirschberg, we excluded pregnancy from our project scope. The advice was to avoid a live bacterial therapeutic during pregnancy. Because our therapy is aimed at people of reproductive age, any treatment targeting that population has to account for unplanned exposure.
Mahnaz Bahri-Khomami specified what would need to be established if the project were to move further: whether the therapeutic or its byproducts cross the placenta and whether 5β-reduction of androgens could affect male fetal development. Conventional probiotics are widely used during pregnancy, but the safety of genetically engineered probiotics has not yet been established.
Advancing the engineering system
Validating Enzyme Function
The immediate experimental priority is to obtain enzyme preparations of sufficient purity and reproducibility to interpret activity measurements confidently. Future work on enzyme activity will add:
- targeted LC–MS/MS with appropriate analytical standards, to assess if testosterone is depleted and the expected product is formed.
- androgen receptor assays: to assess whether the treated sample produce less androgen receptor activation.
From purified enzymes to a probiotic engineered chassis
Activity in a purified-enzyme assay does not establish that the same reaction occurs effectively inside a bacterium therefore we will need to transfer the engineered system into the probiotic strain such as Escherichia coli Nissle 1917 and introduce whole-cell studies to examine substrate access, enzyme expression, cofactorA small molecule an enzyme needs alongside it to carry out its reaction, here NADPH. availability and the fate of the reaction products.
Testing under gut-like conditions, including low oxygen availability, relevant pH and bile exposure, would help determine if activity can be maintained in the intended intestinal setting.
In silico experimentation
- Consensus docking: Re-dock the top variants with a second tool (e.g. GNINA or DiffDockDocking programs that use deep learning to place and score the molecule.) and keep only the variants that rank well in both.
- Other steroids: Dock the top variants against related steroids that could compete in the cell, to see whether the testosterone preference holds beyond progesterone.
- Cofactor in the model: Add NADPH supply to the activity model, since the reaction depends on it.
- Dose and conditions: Run the integrated model for different starting steroid concentrations, culture densities and induction timings, to find the conditions where the preference is largest.
- Experimental values in the model: The model can be run again with the measured activity values in place of the docking scores, to see how the predictions change.
Future Implementation
Biosafety
Our project is a proof of concept and its safety features have not completely been tested in our strain. These are the steps we would consider in the future:
- Test the sensing and feedback-responsive loop : Measure the concentration of testosterone at which TeiR switches on and make TeiR specific to testosterone and not other steroids. Furthermore, confirm that TeiR activates the sip48 promoter directly in our chassisThe host organism that carries and runs the engineered genetic system..
- Strengthen Containment (multi-layered biosafety): Combine ΔdapA auxotrophy with a second independent dependency. Develop a hypoxia gated CRISPR based system and to ensure reduced levels of HGT, we should add a CRISPR system that cuts dapA genes acquired from outside since our strain has no dapA gene of its own.
- Study the gut ecosystem and gene transfer: To test whether the effector gene can transfer to other gut bacteria and if the chromosomal integration lowers the risk. Further to test how the engineered strain can lower the testosterone levels and how this reduction affects the resident gut community.
- Regulations: Prepare for preclinical trials before releasing the product into the market.
Pharmacokinetics and ADME
We have not yet measured the residence time of the bacteria in the gut after dosing (pharmacokinetics) and how much the enzyme lowers the testosterone levels (pharmacodynamics). Both are needed to choose a dose and schedule. The ADME framework raises the following questions:
- A (Absorption): absorption normally describes the drug entering the blood, but our bacteria are not meant to enter the blood at all; the question instead is whether potential testosterone breakdown products are absorbed from the gut into the blood.
- D (Distribution): distribution addresses where the drug travels in the body, which for AnTigone translates to where in the gut the bacteria are present and act.
- M (Metabolism): metabolism is normally where the body breaks down the drug, whereas for AnTigone the bacteria metabolise testosterone into less active forms, raising the questions of how the gut microbiota is affected and what it in turn does to those products.
- E (Excretion): excretion describes how the drug leaves the body, and for our probiotic we need to understand how the bacteria themselves are cleared (environmental biocontainment)



